Ligand id: 3465

Name: formoterol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: formoterol

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 4
Rotatable bonds 9
Topological polar surface area 90.82
Molecular weight 344.17
XLogP 2.21
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Formoterol is used to manage the symptoms of asthma and/or chronic obstructive pulmonary disease (COPD). In November 2014, the EU EMA granted marketing authorisation of the fixed-dose combination medication Duaklir Genuair TM (aclidinium bromide/formoterol fumarate) as a maintenance bronchodilator for patients with COPD.
In April 2016, the US FDA approved the fixed-dose inhalation aerosol formulation, glycopyrrolate plus formoterol (Bevespi Aerosphere®) for long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Mechanism Of Action and Pharmacodynamic Effects
Formoterol is a β2-adrenoceptor agonist. The drug causes vasodilation of bronchial smooth muscle to improve breathing.